News

Location:homepage  News

Congratulations on the publication of Jie Ding's paper by Analytical Chemistry!

发表时间:2015-12-01 阅读次数:462次

 

Screening of HER2 Overexpressed Breast Cancer Subtype In Vivo by the Validation of High-Performance, Long-Term, and Noninvasive Fluorescence Tracer

† State Key Laboratory of Analytical Chemistry for Life Science, Collaborative Innovation of Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210093, China
‡ China-America Cancer Research Institute, Guangdong Medical University, Dongguan, Guangdong 523808, China
§ School of Medical Imaging, Xuzhou Medical College, Xuzhou 221004, China
Anal. Chem., 2015, 87 (24), pp 12290–12297
DOI: 10.1021/acs.analchem.5b03580
Publication Date (Web): November 24, 2015
Copyright © 2015 American Chemical Society
*E-mail: jjzhu@nju.edu.cn., *E-mail: zhiweihe688@163.com., *E-mail: jianglp@nju.edu.cn.

Abstract

Abstract Image

The high-performance and noninvasive screening of heterogeneous tumor subtypes in vivo is particularly desirable for the diagnosis and symptomatic treatment of cancer. Therefore, we report a near-infrared (NIR) fluorescence tracer “smartly identified HER2” (SI-HER2) for rapid, accurate, and highly specific screening of HER2 overexpressed breast cancer. An antibody against HER2 protein receptor, EP1045Y, was conjugated with NIR emitting CdSeTe/CdS/ZnS QDs via polyhistidine-driven self-assembly approach. The further adsorption of black hole quencher 3 on antibody enabled a “turn on” fluorescence response of the fluorescence tracer to HER2 protein receptor. Aside from the capability of differentiating the HER2 overexpressed MCF-7 cells from its counterparts, the fluorescence tracer can also accurately and rapidly identify the HER2 overexpressed breast tumor subtype in two tumors-bearing mouse model, providing a platform for the investigation of advanced pathways to distinguish the different breast cancer subtypes.